Fusion Pharmaceuticals’ FPI-2059 shows tumor growth inhibition

Fusion Pharmaceuticals announced the presentation of preclinical data that provide further support of its clinical stage FPI-2059, a neurotensin receptor 1 – NTSR1 – targeted alpha therapy and additional preclinical development programs. Data from preclinical studies of FPI-2059 demonstrates robust FPI-2059 tumor uptake and dose-dependent tumor growth inhibition and therapeutic efficacy in a preclinical colorectal tumor model. These data provide further evidence supporting the clinical development of FPI-2059, which is currently being evaluated in a Phase 1 study for the treatment of solid tumors expressing NTSR1. Data from additional preclinical studies highlight the potential of tumor endothelial marker 1 – TEM-1 – and epidermal growth factor receptor variant 3 as targets for actinium-225 labelled TATs.